BioSpace News Archive

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable global pharmaceutical and biotechnology industry experience and executive-level financial leadership to GW’s Board. “I am very pleased to welco

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Morgan Stanley’s 18th Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, September 17, 2020. Giovanni Caforio, M.D. , Chairman and Chief Executive Officer will answer questions about the co

Pfizer Inc. (NYSE:PFE) announced today that more than 50 abstracts representing data from nine approved and investigational Pfizer medicines, including several biomarker-driven and immuno-therapies, will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 being held from September

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in a Phase 3 clinical trial of DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following catara

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its participation in two upcoming investor conferences.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced its participation at two upcoming investor conferences during the month of September. During these presentations, David Arthur, Chief Executive Officer of Salarius Pharmaceuticals, will provide an overview of Salarius’ business and highlight recent achievements, as well as anticipated upcomin

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in the gene

IntegriChain, a leading data and managed services company helping Life Sciences manufacturers deliver access to innovative therapies that significantly improve patient lives, announced that registration is now open for the Access Insights Virtual Summit 2020, to be held October 20 to 22, 2020.

Preclinical data supports potential for: - Broadly applicable vaccine (young, elderly, immunocompromised) - Rapid onset of immunogenicity within 7 days of the first dose - Thermostabilized vaccine (ambient storage/shipping with no need for cold chain) - Multivalent vaccine formulation, if needed - Readily adaptable vaccine for seasonal vaccination use, if needed [10-September-2020]

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) ( FSE:TQB2), a provider of best-in-class therapeutic antibody discovery capabilities for the global pharmaceutical and biotech industries, is pleased to announce that it has commenced the application process to dual list its